ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,128.44
1.27%
Dow Jones
38,677.30
1.18%
US Dollar vs MXN
16.9606
-0.07%
Brent Oil
82.81
-0.98%
Bitcoin
61,683.29
4.33%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Enanta Pharmaceuticals Inc (ENTA)

  7. Enanta Pharmaceuticals Inc (ENTA) Noticias

ENTA

Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ENTA
FechaHoraFuenteTítuloSímboloCompañía
30/04/202406:10Business WireEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ENTAEnanta Pharmaceuticals Inc
30/04/202406:00Business WireEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerNASDAQ:ENTAEnanta Pharmaceuticals Inc
29/04/202406:00Business WireEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024NASDAQ:ENTAEnanta Pharmaceuticals Inc
17/04/202406:00Business WireEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024NASDAQ:ENTAEnanta Pharmaceuticals Inc
08/03/202416:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
06/03/202406:00Business WireEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
27/02/202412:11Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ENTAEnanta Pharmaceuticals Inc
14/02/202413:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ENTAEnanta Pharmaceuticals Inc
08/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTAEnanta Pharmaceuticals Inc
08/02/202415:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTAEnanta Pharmaceuticals Inc
07/02/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTAEnanta Pharmaceuticals Inc
07/02/202415:01Business WireEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ETNASDAQ:ENTAEnanta Pharmaceuticals Inc
06/02/202406:00Business WireEnanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
31/01/202406:00Business WireEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023NASDAQ:ENTAEnanta Pharmaceuticals Inc
26/01/202415:39Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ENTAEnanta Pharmaceuticals Inc
26/01/202415:37Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ENTAEnanta Pharmaceuticals Inc
26/01/202415:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ENTAEnanta Pharmaceuticals Inc
11/01/202415:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ENTAEnanta Pharmaceuticals Inc
04/01/202406:00Business WireEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
03/01/202406:00Business WireEnanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
12/12/202316:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202315:38Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202315:21Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202315:12Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:ENTAEnanta Pharmaceuticals Inc
22/11/202306:00Business WireEnanta Pharmaceuticals to Participate at Evercore ISI HealthCONx ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
20/11/202315:01Business WireEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ETNASDAQ:ENTAEnanta Pharmaceuticals Inc
20/11/202305:25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:ENTAEnanta Pharmaceuticals Inc
13/11/202306:00Business WireEnanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023NASDAQ:ENTAEnanta Pharmaceuticals Inc
13/10/202306:00Business WireEnanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV PipelineNASDAQ:ENTAEnanta Pharmaceuticals Inc
17/09/202311:00Business WireEnanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ENTA

Su Consulta Reciente

USI
USTECH100
US Tech 100
NYSE
AXP
American Express
NYSE
DIS
Walt Disney
USOTC
BASFY
BASF (QX)
NASDAQ
AAPL
Apple
USOTC
DTEGY
Deutsche Telekom (QX)
FX
USDMXN
US Dollar vs MXN
NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
NYSE
VZ
Verizon Communications
AMEX
XLF
Financial Select Sector
CCOM
SILVER
SILVER
FX
EURUSD
Euro vs US Dollar
NASDAQ
AMZN
Amazon.com
NYSE
JPM
JP Morgan Chase
FX
EURMXN
Euro vs MXN
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados